TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30073497

Group type: EXPERIMENTAL
Intervention: Patients with liver transplant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients without liver transplant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caregivers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients and caregivers
Number of subjects: 60
Study: 30073583

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid plus docetaxel 75 mg/m²
Number of subjects: 10

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m²
Number of subjects: 10
Study: 30073642

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) administered intravenously every 3 weeks until progression or unacceptable toxicity.
Number of subjects: 16
Study: 30074085

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Baermann funnel (BM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Koga agar plate culture (KAP)
Number of subjects: 80
Study: 30074111

Group type: EXPERIMENTAL
Intervention: Beta-Blockers (BB)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: ACE Inhibitors/Angiotensin Receptor Blockers (ACEi/ARB)
Number of subjects: 972
Study: 30074259

Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg orally, once daily in continuous 28-day cycles from day -3, plus intravenous cytarabine 100 mg/m².
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytarabine/daunorubicin (as part of the combination therapy).
Number of subjects: 0
Study: 30074823

Group type: EXPERIMENTAL
Intervention: KOOS, JR augmented with additional KOOS items
Number of subjects: 1904

Group type: COMPARATOR
Intervention: KOOS, JR
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Aggregate score combining KOOS, JR and 4 KOOS Quality of Life subscale questions
Number of subjects: 1904
Study: 30075748

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 10-15 days
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 14 or 15 days
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 10 days
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily
Number of subjects: 858
Study: 30075751

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 100
Study: 30075808

Group type: EXPERIMENTAL
Intervention: Baseline AS-related spinal radiographic alterations and obesity
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: High Bath Ankylosing Spondylitis Metrology Index (BASMI) and exposure to bisphosphonates during follow up
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: mSASSS increase
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Development of new syndesmophytes
Number of subjects: 204
Study: 30076277

Group type: EXPERIMENTAL
Intervention: NGR-hTNF plus doxorubicin
Number of subjects: 28
Study: 30076280

Group type: EXPERIMENTAL
Intervention: MRD-directed IFN-α treatment
Number of subjects: 0
Study: 30076523

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 149
Study: 30076946

Group type: EXPERIMENTAL
Intervention: Chemotherapy group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 30077018

Group type: EXPERIMENTAL
Intervention: Mild OSA-ND group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mild OSA-D group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mild OSA group
Number of subjects: 120
Study: 30077125

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks
Number of subjects: 89
Study: 30077741

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30077990

Group type: EXPERIMENTAL
Intervention: High-sensitive troponin T (hs-TropT)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 92
Study: 30077993

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair with the MitraClip device
Number of subjects: 78
Study: 30078410

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0
Study: 30079331

Group type: EXPERIMENTAL
Intervention: Group A (score ≤2, no or low damage)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (score >2, high damage)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 120
Study: 30079388

Group type: EXPERIMENTAL
Intervention: High tie ligation
Number of subjects: 331

Group type: COMPARATOR
Intervention: Low tie ligation
Number of subjects: 331
Study: 30079464

Group type: EXPERIMENTAL
Intervention: Transcutaneous laryngeal ultrasound (TCLUS) pre- and post-operatively
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined assessment of TCLUS, subjective evaluation, and VFDV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subjective assessment of VF mobility
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vocal fold displacement velocity (VFDV) estimation
Number of subjects: 100
Study: 30079582

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) drug levels < 200 ng/ml or undetectable desethylchloroquine
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (MASRI < 80%)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 305
Study: 30080739

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Preoperative CTCs subpopulations
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Risk assessment score based on tCTCs increase
Number of subjects: 200
Study: 30081223

Group type: EXPERIMENTAL
Intervention: EG Scan II (transnasal capsule endoscope)
Number of subjects: 200

Group type: COMPARATOR
Intervention: C-EGD (conventional esophagogastroduodenoscopy)
Number of subjects: 200
Study: 30081838

Group type: EXPERIMENTAL
Intervention: Ongoing treatment with zidovudine (76% of children, median duration 48 months (26-74))
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Previous treatment with stavudine (18% of children, median treatment duration 8 months (5-25))
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Ongoing treatment with lopinavir/ritonavir (27% of children, median duration 49 months (23-59))
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Boys vs. girls
Number of subjects: 254
Study: 30081845

Group type: EXPERIMENTAL
Intervention: Fit for Dialysis film
Number of subjects: 30
Study: 30081846

Group type: EXPERIMENTAL
Intervention: Decision aid administered prior to specialist consultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision aid administered within the consultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of both decision aids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 30081857

Group type: EXPERIMENTAL
Intervention: Gut microbiota and stool short chain fatty acids (SCFAs) measurement
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Annual measures of obesity risk factors (body composition, physical activity, dietary intake)
Number of subjects: 2500
Study: 30081858

Group type: EXPERIMENTAL
Intervention: Women approached following a stillbirth (case)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Women approached during pregnancy (control)
Number of subjects: 12
Study: 30081865

Group type: EXPERIMENTAL
Intervention: Adjuvant HAI oxaliplatin plus systemic LV5FU2
Number of subjects: 114

Group type: COMPARATOR
Intervention: Adjuvant systemic FOLFOX
Number of subjects: 114
Study: 30081867

Group type: EXPERIMENTAL
Intervention: Quizartinib 135 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quizartinib 90 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quizartinib (both doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 13
Study: 30081933

Group type: EXPERIMENTAL
Intervention: ENABLE CHF-PC plus usual heart failure care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 30081937

Group type: EXPERIMENTAL
Intervention: Psychological resilience measured by the Connor-Davidson Resilience scale (CD-RISC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life measured by SF-36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood sample collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of smoking, exercise habits, BMI, trust in treatment, and satisfaction with care
Number of subjects: 0
Study: 30081967

Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention delivered by trained family peers
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention delivered by community health workers
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual care comprising mental health care support materials and school support materials
Number of subjects: 3000
Study: 30082172

Group type: EXPERIMENTAL
Intervention: Excellent glycemic control (mean HbA1c <7.2%)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Poor glycemic control (mean HbA1c >8.8%)
Number of subjects: 240
Study: 30082340

Group type: EXPERIMENTAL
Intervention: SH003 (1 to 4 tablets, three times a day for 3 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SH003 (dose escalation)
Number of subjects: 6
Study: 30082349

Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sorbitol syrup (control)
Number of subjects: 236
Study: 30082361

Group type: EXPERIMENTAL
Intervention: Trained volunteers assisting patients during weekday lunchtime and evening meals
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cost-saving aspect of the intervention
Number of subjects: 65
Study: 30082366

Group type: EXPERIMENTAL
Intervention: ICF core set identification through systematic review, qualitative interviews, online surveys, and cross-sectional study.
Number of subjects: 0
Study: 30082367

Group type: EXPERIMENTAL
Intervention: Shaping Healthy Minds - a modular transdiagnostic intervention for mood, stressor-related and anxiety disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30082474

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent options
Number of subjects: 0
Study: 30082475

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg b.i.d. plus rituximab 375 mg/m2
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg b.i.d. plus rituximab and vincristine
Number of subjects: 45
Study: 30082489

Group type: EXPERIMENTAL
Intervention: High HI-T (>1.9) and high MAX-T (>10.5)
Number of subjects: 42
Study: 30083405

Group type: EXPERIMENTAL
Intervention: Suspected obstructive sleep apnea (OSA) patients
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Treatment modality and compliance
Number of subjects: 10000
Study: 30083748

Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir on posttransplant day 3
Number of subjects: 20
Study: 30084702

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study: 30084880

Group type: EXPERIMENTAL
Intervention: MonAmour test
Number of subjects: 91

Group type: COMPARATOR
Intervention: Reference standard tests (Bells test, Apples test, Neglect subtest of the Test for Attentional Performance)
Number of subjects: 91
Study: 30084943

Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 4 weeks (PK2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 12 weeks (PK3)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Efavirenz 400 mg (EFV400) without coadministration (PK1)
Number of subjects: 26
Study: 30085018

Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (5 min analysis)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (1 min analysis)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (5 min analysis with good signal quality)
Number of subjects: 592
Study: 30085139

Group type: EXPERIMENTAL
Intervention: 2-dose schedule of bivalent HPV vaccine (bHPV)
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Booster dose of either bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV)
Number of subjects: 1629

Group type: COMPARATOR
Intervention: 3-dose schedule of bivalent HPV vaccine (bHPV)
Number of subjects: 1629
Study: 30085409

Group type: EXPERIMENTAL
Intervention: FAST PLUS test
Number of subjects: 435
Study: 30086261

Group type: EXPERIMENTAL
Intervention: Small-bowel capsule endoscopy (CE)
Number of subjects: 74
Study: 30086408

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 128
Study: 30086649

Group type: EXPERIMENTAL
Intervention: Increased protein intake diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard protein intake diet
Number of subjects: 25
Study: 30086682

Group type: EXPERIMENTAL
Intervention: Decreased trigeminal nerve volume in primary trigeminal neuralgia patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduced grey matter volume in primary trigeminal neuralgia patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mediation analysis of trigeminal nerve volume and pain ratings
Number of subjects: 80
Study: 30086729

Group type: EXPERIMENTAL
Intervention: Multi-parametric model combining host and pathogen data for distinguishing between bacterial and viral infections.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: New host- or pathogen-related biomarkers used to generate a multi-parametric model.
Number of subjects: 1200
Study: 30086777

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg BID, with incremental increases of 5 mg BID at weeks 12 and 18 (maximum 20 mg BID)
Number of subjects: 45
Study: 30086774

Group type: EXPERIMENTAL
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cyanoacrylate adhesive (CAE)
Number of subjects: 180
Study: 30086778

Group type: EXPERIMENTAL
Intervention: Electronic decision support system (EDSS) used by trained nurse care coordinators (NCCs) with regular SMSs to patients for 12 months
Number of subjects: 1876

Group type: COMPARATOR
Intervention: Standard treatment arm (paper-based hypertension treatment guidelines)
Number of subjects: 1876

Group type: EXPERIMENTAL
Intervention: Electronic decision support system (EDSS) used by trained nurse care coordinators (NCCs)
Number of subjects: 1876
Study: 30086783

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Risk score including diabetes, hemoglobin and ECV > 33%
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Tertiles of the probability score
Number of subjects: 118
Study: 30087028

Group type: EXPERIMENTAL
Intervention: Momelotinib 150 mg twice daily combined with trametinib 1.0 mg once daily
Number of subjects: 21
Study: 30087093

Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood pressure (TELEM) group
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Telemonitoring by text message (TELEMEV) group
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: TELEM-TELEMEV group
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual clinical treatment (UCT) group
Number of subjects: 231
Study: 30087197

Group type: EXPERIMENTAL
Intervention: Rescue medication availability in the home
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Medication readiness criteria
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Controller medication availability in the home
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Controller medication readiness criteria
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Beliefs about medications
Number of subjects: 288
Study: 30087626

Group type: COMPARATOR
Intervention: Translocator Protein Density measurement
Number of subjects: 0
Study: 30087850

Group type: EXPERIMENTAL
Intervention: Four cycles of chemotherapy
Number of subjects: 40
Study: 30088048

Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg/day with Carboplatin AUC6 (A/C)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day with Carboplatin AUC6 (A/C)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg/day with Carboplatin AUC6 and Paclitaxel 175 mg/m2 (A/C/P)
Number of subjects: 38
Study: 30088146

Group type: EXPERIMENTAL
Intervention: PANSS total score for women
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS total score for men
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS negative score and PANSS affective score in women
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS positive score and PANSS affective score in men
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS affective score in women
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PANSS affective, positive, and cognitive scores in men
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: HRQoL reported by men
Number of subjects: 1379
Study: 30088161

Group type: EXPERIMENTAL
Intervention: mDCF plus trastuzumab
Number of subjects: 26
Study: 30088178

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study: 30088198

Group type: EXPERIMENTAL
Intervention: HBsAg-based recombinant vaccine administered every 8 weeks for 48 weeks (seven doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Age-, gender-, and baseline HBsAg-matched control group
Number of subjects: 20
Study: 30088336

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) 3.4 MJ/810 kcal daily for 8 weeks
Number of subjects: 2224
Study: 30088802

Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements before and after inhaled albuterol (1 week before anticipated hospital discharge)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements in PROP infants with BPD
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements in PROP infants with respiratory disease
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Bronchodilator response
Number of subjects: 765

Group type: COMPARATOR
Intervention: Comparison with term infants
Number of subjects: 765
Study: 30089118

Group type: EXPERIMENTAL
Intervention: Electronic clinical prediction rule (CPR) combined with AKI e-alert
Number of subjects: 30295

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30295
Study: 30089160

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 30089406

Group type: EXPERIMENTAL
Intervention: Sodium <20 mmol/L
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sodium >20 mmol/L
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 200
Study: 30089457

Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy at 40.0 Gy/2.5 Gy with concurrent S-1 at 80 mg/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy
Number of subjects: 9
Study: 30089523

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication use review
Number of subjects: 900
Study: 30089568

Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR) monitoring
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ILR monitoring
Number of subjects: 71
Study: 30089664

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 68
Study: 30089716

Group type: EXPERIMENTAL
Intervention: Progressors≥5
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Progressors<5
Number of subjects: 75

Group type: COMPARATOR
Intervention: aAb- relatives
Number of subjects: 75
Study: 30091085

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 87
Study: 30091207

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy followed by Non-Ablative Fractionated Laser (NAFL) treatment
Number of subjects: 30
Study: 30091209

Group type: EXPERIMENTAL
Intervention: High adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Medium adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019

Group type: COMPARATOR
Intervention: Low adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019
Study: 30091600

Group type: EXPERIMENTAL
Intervention: ASTX660 (1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one)
Number of subjects: 0
Study: 30092621

Group type: EXPERIMENTAL
Intervention: Prophylactic mesh reinforcement
Number of subjects: 4679

Group type: COMPARATOR
Intervention: Non-mesh controls
Number of subjects: 4679
Study: 30092840

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (MSCs) and biphasic calcium phosphate granules as scaffolds
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study: 30092843

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus complete mesogastrium excision (D2 + CME)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Conventional D2 lymphadenectomy
Number of subjects: 336
Study: 30092965

Group type: EXPERIMENTAL
Intervention: Anthracycline therapy (Doxorubicin)
Number of subjects: 27
Study: 30093048

Group type: EXPERIMENTAL
Intervention: Low CFR (Coronary Flow Reserve)
Number of subjects: 519

Group type: COMPARATOR
Intervention: High CFR
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Low CFR among patients with high FFR (Fractional Flow Reserve)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Low FFR and low CFR
Number of subjects: 519

Group type: COMPARATOR
Intervention: High FFR
Number of subjects: 519
Study: 30093147

Group type: EXPERIMENTAL
Intervention: Preterm Human Milk (PT HM)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Term Human Milk (T HM)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both PT HM and T HM
Number of subjects: 500